Human prostatic steroid 5 alpha-reductase isoforms--a comparative study of selective inhibitors
Iehlé, Catherine and Délos, Sylvie and Guirou, Olivier and Tate, Rothwell and Raynaud, Jean-Pierre and Martin, Pierre-Marie (1995) Human prostatic steroid 5 alpha-reductase isoforms--a comparative study of selective inhibitors. Journal of Steroid Biochemistry and Molecular Biology, 54 (5-6). pp. 273-279. ISSN 0960-0760 (https://doi.org/10.1016/0960-0760(95)00134-L)
Full text not available in this repository.Request a copyAbstract
The present study describes the independent expression of the type 1 and 2 isoforms of human 5 alpha-reductase in the baculovirus-directed insect cell expression system and the selectivity of their inhibition. The catalytic properties and kinetic parameters of the recombinant isozymes were consistent with published data. The type 1 isoform displayed a neutral (range 6-8) pH optimum and the type 2 isoform an acidic (5-6) pH optimum. The type 2 isoform had higher affinity for testosterone than did the type 1 isoform (Km = 0.5 and 2.9 microM, respectively). Finasteride and turosteride were selective inhibitors of the type 2 isoform (Ki (type 2) = 7.3 and 21.7 nM compared to Ki (type 1) = 108 and 330 nM, respectively). 4-MA and the lipido-sterol extract of Serenoa repens (LSESr) markedly inhibited both isozymes (Ki (type 1) = 8.4 nM and 7.2 micrograms/ml, respectively; Ki (type 2) = 7.4 nM and 4.9 micrograms/ml, respectively). The three azasteroids were competitive inhibitors vs substrate, whereas LSESr displayed non-competitive inhibition of the type 1 isozyme and uncompetitive inhibition of the type 2 isozyme. These observations suggest that the lipid component of LSESr might be responsible for its inhibitory effect by modulating the membrane environment of 5 alpha-reductase. Partially purified recombinant 5 alpha-reductase type 1 activity was preserved by the presence of lipids indicating that lipids can exert either stimulatory or inhibitory effects on human 5 alpha-reductase.
-
-
Item type: Article ID code: 35167 Dates: DateEvent30 September 1995Published13 April 1995AcceptedSubjects: Medicine > Therapeutics. Pharmacology Department: Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences Depositing user: Pure Administrator Date deposited: 02 Nov 2011 11:05 Last modified: 03 Aug 2024 03:43 URI: https://strathprints.strath.ac.uk/id/eprint/35167